CANMAB 440MG INJECTION

Canmab 440mg Injection is a prescription monoclonal antibody therapy containing trastuzumab, a targeted treatment for HER2-positive breast cancer and HER2-positive gastric cancer. This injectable therapy works by specifically binding to HER2 receptors on cancer cells, helping to inhibit tumor growth and improve treatment outcomes. Canmab is administered under strict hospital supervision to ensure patient safety and effectiveness.

Trastuzumab in Canmab blocks the growth signals of HER2-positive cancer cells and activates the immune system to destroy malignant cells. This dual mechanism helps reduce tumor progression, supports combination therapy regimens, and enhances overall clinical outcomes. Canmab 440 mg Injection is widely used in oncology centers for targeted therapy in patients with HER2-overexpressing tumors.

Manufactured in WHO-GMP certified facilities, Canmab 440 mg Injection ensures consistent quality, safety, and efficacy. It is a prescription-only oncology medicine intended for intravenous use in hospital settings. Canmab provides a trusted, clinically proven solution for patients with HER2-positive breast cancer and HER2-positive gastric cancer, supporting effective cancer management when used as part of a comprehensive treatment plan.

Product Features

• Oral chemotherapy tablet
• Contains Capecitabine 500 mg
• Antimetabolite anticancer drug
• Used in breast and colorectal cancers
• Tumor-activated targeted action
• Convenient oral dosage form
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Blocks cancer cell growth by interfering with DNA synthesis
• Targets tumors through tumor-activated conversion to active drug
• Helps manage breast and colorectal cancers effectively
• Supports convenient oral chemotherapy under oncologist’s supervision